STOCKHOLM, Jan. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for treatment of early Alzheimer's...
Hence then, the article about bla for subcutaneous formulation of leqembi accepted in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BLA for subcutaneous formulation of Leqembi® accepted in China )
Also on site :
- 1979 Supertramp Hit, Ranked Among the ‘Greatest Classic Rock Songs’ Ever, Was Partially Recorded in a Bathroom
- Inside ‘Married at First Sight’ Season 20: How Peacock’s Changes Led to 1.8 Billion Minutes Viewed, That Wild Reunion and Why Lindsay Hubbard Said No to the Show
- ‘Big Brother’ Season 28, Week 7 Eviction: A Celebration Of 1,000 Episodes & Another Houseguest Is Voted Out